Effects of batroxobin on sudden deafness: Hearing outcome and coagulation/fibrinolysis

Effects of batroxobin on sudden deafness: Hearing outcome and coagulation/fibrinolysis - Effects of batroxobin on hearing outcome of sudden deafness

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003173

Enrollment

100

Registered

2010-02-12

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden deafness

Interventions

For the patients suffering from sudden deafness, 20BU of batroxobin will be injected for the first day followed by 10BU per 2 days. Final amount of injection will be 110BU of batroxobin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients suffering from sudden deafness who accepted the batroxobin injection therapy after hospitalization.

Exclusion criteria

Exclusion criteria: Patients who do not accept hospitalization. Patients who are not allowed to be injected with batroxobin according to the guidelines for the usage of batroxobin.

Design outcomes

Primary

Measure	Time frame
Hearing changes and coagulation/fibrinolysis data will be correlated and thus effective mechanisms of batroxobin on sudden deafness could be clarified.	—

Secondary

Measure	Time frame
Prognostic factor of batroxobin on sudden deafness could be found through this study.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026